🇺🇸 FDA
Patent

US 11866747

Engineered meganucleases that target human mitochondrial genomes

granted A61KA61K38/00A61K48/005

Quick answer

US patent 11866747 (Engineered meganucleases that target human mitochondrial genomes) held by Precision BioSciences, Inc. expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Precision BioSciences, Inc.
Grant date
Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K38/00, A61K48/005, A61K9/0019, A61K9/5123